共查询到19条相似文献，搜索用时 328 毫秒
1.
采用犬细小病毒单克隆抗体（CPVMcAb）配合静脉注射用犬免疫球蛋白及静脉注射用犬血白蛋白,采用股内侧肌肉注射对172例细小病毒病患犬进行临床治疗试验。共治愈140例,治愈率为81．40％。采取以上治疗方案,结合对症支持治疗,发病1d的患犬治愈率90．70％,发病2d的患犬治愈率为85．29％,发病3d的患犬治愈率为56．25％,发病4d的患犬治愈卒为72．73％,发病5、d的患犬治愈率为77．78％。94．29％的治愈犬（132只）用药后4d内完全康复。采用该治疗方案,进入犬体内的McAb能迅速到达全身各组织,中和淋巴组织及血循环中的病毒,阻止病原复制和扩散;同时,中和反应形成抗原抗体复合物,可促进机体的主动免疫反应,促进患犬逐渐康复。该研究结果对提高犬细小病毒病的临床治疗效果具有积极的应用价值。 相似文献
2.
将临床收集确诊的40只细小病毒病犬分为黄芪多糖组和常规治疗组，对黄芪多糖是否具有治疗犬细小病毒病的作用进行试验研究。并以犬血常规变化来检验其疗效。结果表明：细小病毒病以2～5月龄犬发病较多，并以肠炎型为主。犬感染细小病毒后白细胞数、红细胞数、血红蛋白含量、红细胞压积均低于正常值范围。黄芪多糖能够升高病犬白细胞数、红细胞数、血红蛋白含量，除红细胞数外，在治疗第6天均恢复到正常水平。黄芪多糖能够升高病犬血清中SOD的活性，治疗第6天与基础值比较差异极显著（P〈0．01）；同时能够降低病犬血清中MDA的含量，在治疗第6天与基础值比较差异极显著（〈O．01），与健康对照组相近。黄芪多糖组治愈率为90％．常规治疗组治愈率为70％。 相似文献
3.
采用犬瘟热－细小病毒二联活苗结合它们的强毒组织灭活苗，经不同途径交替免疫成年山羊４次后，抗犬瘟热病毒血清中和抗体效价可达１：１０２４，抗犬细小病毒血凝抑制（ＨＩ）效价达１：２０４８。用该血清制剂对临床感染犬瘟热和病毒性肠炎犬，貉，狐３３６余病例进行跟踪治疗，总有效率可达８５％，治愈率为６８％，本血清具有安全性好，特异性强，治疗效果可靠等优点。 相似文献
4.
对60例犬细小病毒临床病例进行统计与分析。数据显示：犬细小病毒病的成功治愈率为66．7％（40／60）,死亡率为21．7％（13／60）,放弃或预后不清的为11．6％（7／60）;就诊时体温在39℃以上的为40％（24／60）,37℃-39℃为35％（21／60）,37。C以下为30％（2／60）,未测体温为22％（13／60）;15％病例只出现呕吐现象（9／60）,85％都表现剧烈呕吐及腹泻（51／60）,其中出现血便的占35％（18／51）;所有发病犬,未作任何防疫的占58．3％（35／60）,近期防疫过的占41．7％（25／60）,在防疫犬中,44％只防疫一次,66％犬（11／25）约防疫2次-3次;所有发病犬。小于2月龄占16．7％（10／60）,2月龄～5月龄占55％（33／60）,5月龄-12月龄占15％（9／60）,1岁以上犬占5％（3／60）;所有发病犬无明显品种特异性。结果表明,该病具有较高的死亡率,科学防疫、极早诊断和有效治疗是提高本病治疗率的关键。 相似文献
5.
将临床收集确诊的40只细小病毒病犬分为黄芪多糖组和常规治疗组,对黄芪多糖是否具有治疗犬细小病毒病的作用进行试验研究,并以犬血常规变化来检验其疗效。结果表明：细小病毒病以2～5月龄犬发病较多,并以肠炎型为主。犬感染细小病毒后白细胞数、红细胞数、血红蛋白含量、红细胞压积均低于正常值范围。黄芪多糖能够升高病犬白细胞数、红细胞数、血红蛋白含量,除红细胞数外,在治疗第6天均恢复到正常水平。黄芪多糖能够升高病犬血清中SOD的活性,治疗第6天与基础值比较差异极显著（P〈0．01）;同时能够降低病犬血清中MDA的含量,在治疗第6天与基础值比较差异极显著（P〈0．01）,与健康对照组相近。黄芪多糖组治愈率为90％,常规治疗组治愈率为70％。 相似文献
6.
本研究旨在明确猪脾转移因子（TF）对猪繁殖与呼吸综合征（PRRS）活疫苗（CH-1R株）免疫抗体的影响,采用具有自主知识产权的中国发明专利制备3批猪脾TF,将PRRS活疫苗（CH-1R株）单独或分别与3批TF联合（单独免疫组、联合免疫组1、联合免疫组2和联合免疫组3）免疫PRRS抗体阴性仔猪,并设立非免疫空白组,采用ELISA方法检测PRRS抗体水平。结果显示,免疫后第7 d、14 d、28 d、42 d和56 d,联合免疫组1、联合免疫组2和联合免疫组3的PRRS抗体阳性率均比单独免疫组高20%～40%。结果表明,TF可以提高PRRS活疫苗（CH-1R株）的免疫抗体水平,为PRRS防控提供参考。 相似文献
7.
用犬细小病毒高免血清以肢内侧肌肉注射、腹腔注射、静脉滴注三种不同注射途径对87例患犬细小病毒性肠炎病大进行治疗，结果治愈率为68．2％、75.9％、91.7％。大多数病犬康复时间分别为4天、3天、2天。其中静脉滴注治愈率明显高于肌肉注射（P＜0．05），且康复时间也最短。 相似文献
8.
陈上永 《江西畜牧兽医杂志》2022,(3):16-19
为了解猪脾转移因子（TF）对伪狂犬病（PR）活疫苗（Bartha-K61株）免疫抗体的影响,本研究采用本课题组具有自主知识产权的中国发明专利制备3批猪脾TF,将PR活疫苗（Bartha-K61株）单独（单独免疫组）、分别与3批TF联合（联合免疫组1、联合免疫组2和联合免疫组3）免疫PR病毒（PRV）gB抗体阴性仔猪,并设立非免疫空白组,采用ELISA方法检测PRV抗体水平。结果显示,免疫后第7 d、14 d、28 d、42 d和56 d,联合免疫组1、联合免疫组2和联合免疫组3的PRV免疫抗体阳性率分别比单独免疫组高30%～40%、20%～40%、0%、20%和40%～50%。说明TF可以提高PR活疫苗（Bartha-K61株）的免疫抗体水平,为PR的防控提供参考。 相似文献
9.
对探讨一种对细小病毒病患犬能提高治愈率和缩短治愈疗程的有效方法，作者选和了细小病毒患犬１８０只，随机分成３组每组６０只，采用ＴＦ等不同联合用药的综合疗法，进行试验观察，在治疗的第７天进行临床癍状，病程进展的和治疗效果的判定。结果表明：１．抗生素＋补液＋对症治疗组，共治疗患犬６０只，７天内治愈３３只，显效８只，计见效４１只，有效率为６８．３３％；未见效１９只，无效率为３１；６７％。在７天内治愈的３３ 相似文献
10.
犬细小病毒病是由犬细小病毒（cpv）引起的一种急性传染病，发病率和死亡率比较高，达10％～50％，自愈率〈5％．笔者在近一年中的犬病治疗过程中用犬细小病毒快速诊断试纸条确诊为犬细小病毒病的有16例。经过临床治疗得出，除了采用高免血清和对症治疗外，治愈率的高低在很大程度上取决于输液，此外对病犬的护理正确精细与否也有一定的关系。本文重点介绍了犬细小病毒病的临床症状、剖检变化、鉴别诊断、治疗情况及治疗体会。 相似文献
11.
S E Stann R F DiGiacomo W E Giddens J F Evermann 《Journal of the American Veterinary Medical Association》1984,185(6):651-655
From June 1980 through May 1982, 161 pound-source dogs that developed diarrhea while being used in research were evaluated to determine whether canine parvovirus (CPV) type 2 was the etiologic agent. Evaluation included notation of clinical signs, determination of serum CPV-specific immunoglobulin (Ig) M and IgG titers, virus isolation attempts, and histologic examination of tissues. Criteria for diagnosis of canine parvoviral enteritis were serum CPV-specific IgM antibodies, isolation of CPV from feces, and histologic evidence of intestinal crypt cell necrosis. Upon arrival, 67 clinically normal pound-source dogs were evaluated to determine the prevalence of fecal shedding of CPV and to determine their antibody titers to CPV. Parvovirus was not isolated from any of these dogs, although 76% had IgG antibodies and 3% had IgM antibodies. Of the 161 dogs with diarrhea, 40 (25%) had parvoviral enteritis. Of dogs with parvoviral enteritis, 71% had IgG antibodies and 68% had IgM antibodies. Canine parvovirus was isolated from 18 dogs. Serum IgG antibodies were found in 85% of dogs with diarrhea due to other causes. The geometric mean titer of IgG antibodies to CPV was not significantly different among the 3 groups. Clinical signs that appeared significantly (P less than 0.05) more often in dogs with parvoviral enteritis included bloody diarrhea, anorexia, fever (greater than or equal to 39.4 C), and leukopenia (WBC less than 6,000/mm3). Cases occurred throughout the year, without apparent seasonal variation. The duration between arrival and onset of diarrhea was significantly (P less than 0.05) shorter for dogs with parvoviral enteritis.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
12.
13.
14.
15.
按标准方法提取制备了猪的转移因子（transfer factor, TF）,用吞噬杀伤试验MTT法检测了供试杂种牧羊犬肌肉注射猪TF后外周血中性粒细胞吞噬杀伤活性的变化。试验摸索出MTT法测定犬外周血中性粒细胞吞噬杀伤大肠杆菌的最佳条件为：中性粒细胞浓度1.3×106个/ml、大肠杆菌浓度6×105个/ml 时,大肠杆菌和中性粒细胞混合培养2 h,加入MTT后继续培养4 h。体外试验结果表明,猪TF浓度在0.052～1.56 mg/ml范围内,能够明显促进中性粒细胞吞噬杀菌作用,当猪TF浓度为1.56 mg/ml时,对中性粒细胞杀菌活性的影响最大。体内试验结果表明,注射猪TF后第2 d,外周血中性粒细胞数量最高,中性粒细胞吞噬杀菌能力最强。 相似文献
16.
Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial 总被引：3，自引：0，他引：3
Martin V Najbar W Gueguen S Grousson D Eun HM Lebreux B Aubert A 《Veterinary microbiology》2002,89(2-3):115-127
Canine parvoviral enteritis continues to cause significant morbidity and mortality in dogs worldwide, and efficacious antiviral therapies are lacking. The present trial was aimed at evaluating the therapeutic efficacy of a recombinant feline interferon (type omega) preparation in the treatment of parvoviral enteritis in dogs. A double-blind, placebo-controlled challenge trial was performed in beagle pups (8-9 weeks); clinical signs, body weight, hematologic parameters, and mortality were monitored for a period of 14 days after challenge. Fourteen animals were inoculated with virulent canine parvovirus; 10 animals that developed clinical signs thereby meeting the inclusion criteria were admitted to the treatment phase in two randomly selected groups (placebo and IFN) of equal size. The IFN group received daily intravenous injections of rFeIFN-omega (2.5 MU/kg) for three consecutive days. The placebo group received daily injections of saline without IFN. Both groups of animals received individual supportive treatment consisting of adjusted diet and electrolyte solution.All five dogs in the placebo group developed fulminating enteritis with typical clinical signs and died within 10 days post-inoculation (or 6 days post-treatment). In the IFN-treated group, one animal died on day 2 after the treatment was started, whereas the other four dogs survived the challenge and gradually recovered. Our data confirm that the rFeIFN-omega can exert a significant therapeutic effect on dogs with parvoviral enteritis by improving clinical signs and reducing mortality. 相似文献
17.
Tarello W 《Acta veterinaria Hungarica》2003,51(1):73-90
Medical records of thirty-five consecutive cases of canine granulocytic ehrlichiosis (CGE) diagnosed cytologically in Central Italy in 1995-2000 were analysed retrospectively. Tick exposure was reported in 16 dogs (45.7%) and concurrent babesiosis in 19 dogs (54.3%). Ehrlichia-like inclusion bodies were found in neutrophils in a percentage varying from 0.5% to 11%. Frequently recorded clinical signs included anorexia (71.4%), lethargy (45.7%), conjunctivitis (31.4%), fever (25.7%), lameness (20%) and ataxia (20%). Among the 16 representative dogs in which protein, electrophoresis was performed, 10 (62.5%) showed high globulin levels and 6 (37.5%) had concurrent high total protein levels. During treatment with doxycycline, all associated symptoms, including those unusually described, such as pyoderma intertrigo, erythema, apparent blindness and oral papillomatosis, progressively disappeared in 31 (89%) out of 35 dogs. The efficacy of treatment was marked in dogs simultaneously treated twice with imidocarb dipropionate: among the 14 dogs in which a fast recovery was noted, 11 (80%) were concurrently affected by babesiosis and consequently treated with the specific medicament leading to excellent outcomes. The main conclusion is that CGE is present among dogs from Central Italy and should be included in the differential diagnosis of possible zoonotic agents affecting the canine population. 相似文献
18.
Christy A McKnight Roger K Maes Annabel G Wise Matti Kiupel 《Journal of veterinary diagnostic investigation》2007,19(4):409-413
Diagnosis of canine parvovirus type 2 and feline panleukopenia virus infection in dogs and cats may be hampered by the severity of enteric lesions, secondary bacterial overgrowth, and rapid onset of autolysis. In contrast to small intestine, tongue epithelium is less sensitive to postmortem changes. Sections of tongue and small intestine from 11 dogs and 11 cats with a clinical history and gross and microscopic lesions compatible with canine and feline parvoviral infection were examined for parvoviral infection using real-time polymerase chain reaction (PCR), immunohistochemistry (IHC), and direct fluorescent antibody testing (FA). Parvoviral DNA was detected by PCR in both small intestine and tongue of all but 1 dog. Nineteen of 22 animals (86%) with suspect or positive FA staining in the small intestine also had positive FA and IHC staining in the tongue. Three of 3 dogs (100%) whose carcasses had been frozen and thawed prior to necropsy had more consistently positive staining in tongue than in small intestine by FA and IHC. These data confirm tongue as an excellent complementary sample for parvoviral testing in dogs and cats, especially in cases in which postmortem autolysis has occurred. 相似文献
19.
Michelle R. Savigny DVM MS DACVECC Douglass K. Macintire DVM MS DACVIM DACVECC 《Journal of Veterinary Emergency and Critical Care》2010,20(1):132-142
Objective – To determine if oseltamivir with standard therapy for canine parvoviral enteritis ameliorates disease morbidity, mortality, or both; to document significant adverse effects associated with its use.
Design – Prospective, randomized, blinded, placebo-controlled clinical trial.
Setting – University veterinary teaching hospital.
Animals – Thirty-five dogs.
Interventions – Standard therapy was administered to all dogs. Treatment dogs also received oseltamivir, while control dogs received an equivalent volume of placebo.
Measurements and Main Results – Dogs were monitored daily according to a clinical scoring system, physical parameters, and diagnostic evaluations. Dogs in the treatment group gained a significant percentage of weight during hospitalization (mean, +2.6%; SD, 7.1%) versus the control dogs (mean, −4.5%; SD, 6.9%) ( P =0.006). Treatment dogs did not have any significant changes in their white blood cell (WBC) count, while control dogs experienced a significant drop in their WBC counts during their initial stay. In addition, it did not appear that oseltamivir use was associated with any major adverse clinical effects.
Conclusions – While a clear advantage to the use of oseltamivir was not established, a significant weight loss during hospitalization, as well as a significant decrease in WBC count were documented in the control group. No major adverse effects were identified that could be associated with oseltamivir administration. Based on these results, the true role of oseltamivir in the treatment of parvoviral enteritis remains speculative, although it is believed that further investigation is warranted. 相似文献
Design – Prospective, randomized, blinded, placebo-controlled clinical trial.
Setting – University veterinary teaching hospital.
Animals – Thirty-five dogs.
Interventions – Standard therapy was administered to all dogs. Treatment dogs also received oseltamivir, while control dogs received an equivalent volume of placebo.
Measurements and Main Results – Dogs were monitored daily according to a clinical scoring system, physical parameters, and diagnostic evaluations. Dogs in the treatment group gained a significant percentage of weight during hospitalization (mean, +2.6%; SD, 7.1%) versus the control dogs (mean, −4.5%; SD, 6.9%) ( P =0.006). Treatment dogs did not have any significant changes in their white blood cell (WBC) count, while control dogs experienced a significant drop in their WBC counts during their initial stay. In addition, it did not appear that oseltamivir use was associated with any major adverse clinical effects.
Conclusions – While a clear advantage to the use of oseltamivir was not established, a significant weight loss during hospitalization, as well as a significant decrease in WBC count were documented in the control group. No major adverse effects were identified that could be associated with oseltamivir administration. Based on these results, the true role of oseltamivir in the treatment of parvoviral enteritis remains speculative, although it is believed that further investigation is warranted. 相似文献